Immunome Inc. (IMNM) News

Immunome Inc. (IMNM): $20.58

0.44 (-2.09%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add IMNM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#210 of 360

in industry

Filter IMNM News Items

IMNM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest IMNM News From Around the Web

Below are the latest news stories about IMMUNOME INC that investors may wish to consider to help them evaluate IMNM as an investment opportunity.

Immunome to Present at the Stifel 2023 Healthcare Conference

SEATTLE & EXTON, Pa., November 10, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.

Yahoo | November 10, 2023

Immunome Reports Third Quarter 2023 Financial Results

SEATTLE & EXTON, Pa., November 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Yahoo | November 9, 2023

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

SEATTLE & EXTON, Pa., November 08, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques "JJ" Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.

Yahoo | November 8, 2023

7 Biotech Stocks to Get In Now Before Investors Catch On

Biotech stocks are down, but there are hidden gems among the rubble.

John Blankenhorn on InvestorPlace | October 23, 2023

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

SEATTLE & EXTON, Pa., October 19, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research.

Yahoo | October 19, 2023

Insider Buying: Immunome Inc's President and CEO Clay Siegall Acquires 169,204 Shares

On October 2, 2023, Clay Siegall, the President and CEO of Immunome Inc (NASDAQ:IMNM), made a significant insider purchase of 169,204 shares of the company.

Yahoo | October 5, 2023

Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies

SEATTLE & EXTON, Pa., October 03, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it has completed its previously announced merger with Morphimmune.

Yahoo | October 3, 2023

Individual investors who hold 51% of Immunome, Inc. (NASDAQ:IMNM) gained 15%, institutions profited as well

Key Insights Immunome's significant individual investors ownership suggests that the key decisions are influenced by...

Yahoo | October 1, 2023

Inside the deal: How Immunome and MophImmune came to a merger agreement

A fortuitous chain of events led to a merger and a $125 million PIPE financing deal, both of which are expected to be completed next month.

Yahoo | August 18, 2023

Immunome Reports Second Quarter 2023 Financial Results

EXTON, Pa., August 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Yahoo | August 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!